# Samsung Bioepis: substitution access does not override the purchasing channel Expanded HADLIMA interchangeability removes a regulatory friction while leaving payer access and partner economics unresolved. Canonical: https://kgcf.dsmlholdings.com/insights/samsung-bioepis-hadlima-expanded-interchangeability/ Published: 2026-10-08 Author: [DSML Holdings LLC](https://www.dsmlholdings.com/) Company: Samsung Bioepis Event: 2025-05-27 Dated announcement of the additional May FDA interchangeability designations; not an assertion that the agency letters were issued on the press-release day. ## Reported metrics - Announced autoinjector presentations: 40 mg / 0.4 mL and 40 mg / 0.8 mL. High- and low-concentration presentations in the May announcement; scope measure, not patient volume or comparative efficacy.. [Source 1](https://www.organon.com/news/us-food-and-drug-administration-fda-grants-interchangeability-designation-to-samsung-bioepis-and-organon-hadlima-adalimumab-bwwd-injection/) ## Reported evidence Samsung Bioepis and Organon announced on May 27, 2025 that FDA interchangeability designations had been added for HADLIMA high- and low-concentration autoinjectors and the high-concentration prefilled syringe. The release distinguishes these from designations received for other presentations in June 2024. Substitution remains subject to state pharmacy laws. Organon's February 24, 2026 annual filing corroborates the expanded status and its commercial-rights scope. This is a regulatory access milestone for an already marketed product, not a new initial drug approval or a demonstrated sales increase. ## Investment interpretation Interchangeability can make a product easier to use through a pharmacy channel, but it is not a command to purchasers or an assurance of margin. The Korean developer's economic gain depends on the commercial partner converting that access into demand on terms that still support supply contribution. The milestone is best understood as one reduction in transaction friction within a competitive, contract-driven market. ## Economic assessment Regulatory access, formulary access and cash receipts sit on different layers. A product can be substitutable where law permits while remaining less favored by a particular purchasing arrangement. The relevant developer receipts depend on its agreement with Organon, not solely on a reference-product list price. Costs for manufacturing, device presentations, support and inventory must be measured against collected consideration. No incremental Samsung Bioepis sales or profit attributable to the designation is disclosed in these sources. ## The Presentations Matter The announcement identifies specific presentations and distinguishes the newly expanded designation from earlier status. That detail prevents an inaccurate claim that the product first became interchangeable in every form on the announcement date. Presentation choice affects how a medicine enters a pharmacy workflow and how patients and providers use it. It can therefore influence adoption without implying a difference in clinical efficacy between an interchangeable and another approved biosimilar. A supply plan also needs to match the presentations buyers actually request. Different concentration and delivery-device combinations can create separate stock-keeping and inventory requirements. A broad regulatory offering may improve competitive coverage while increasing operational complexity. The developer must manage forecast mix and avoid excess inventory in a less-used format. Counting approved presentations as independent business events or as guaranteed demand would miss the economics of supporting the complete product range. 1. [Organon and Samsung Bioepis / expanded HADLIMA interchangeability](https://www.organon.com/news/us-food-and-drug-administration-fda-grants-interchangeability-designation-to-samsung-bioepis-and-organon-hadlima-adalimumab-bwwd-injection/) ## Substitution Is Conditional Access The release explicitly qualifies pharmacy substitution by state law. It should not be translated into an unconditional right to replace every prescription in every setting. Payer arrangements, patient needs and dispensing procedures can still determine which product is used. The designation reduces a particular prescriber-consultation friction where the rules permit; it does not eliminate the broader purchasing process. This is why regulatory parity alone may not establish commercial differentiation in a biosimilar market. Other suppliers can compete through contracts, reliability and presentation availability. A developer needs evidence that the additional access changes actual use, not merely evidence that the designation exists. Repeat dispensing, payer coverage and net price would help establish that bridge. The press release provides no controlled measurement of incremental uptake attributable to the May expansion. 1. [Organon and Samsung Bioepis / expanded HADLIMA interchangeability](https://www.organon.com/news/us-food-and-drug-administration-fda-grants-interchangeability-designation-to-samsung-bioepis-and-organon-hadlima-adalimumab-bwwd-injection/) 2. [Organon / complete FY2025 Form 10-K, rights and product status](https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/ogn-20251231.htm) ## Commercial Rights Are Geographically Bounded Organon's annual filing describes commercialization rights with excluded territories. That scope matters because a global product brand does not imply one uniform economic channel. The Korean manufacturer and partner may have different roles in different countries, and national access decisions can occur at different times. The US interchangeability event cannot be used to infer unrestricted partner rights in Korea, China or the European Union. The same filing is stronger evidence of the partner's business structure than a generic claim that a multinational organization distributes worldwide. Yet it still does not establish the Korean supplier's specific retained margin for this product. A credit assessment should follow the licence, supply contract and remittance basis. Worldwide reference-product revenue is not a substitute for a legally bounded claim, and excluding certain territories should not be treated as evidence that another named channel has already delivered sales there. 2. [Organon / complete FY2025 Form 10-K, rights and product status](https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/ogn-20251231.htm) ## Gross Price And Net Contribution The commercial opportunity is to gain use without losing the contribution required to support manufacturing and continued quality obligations. A lower price can help access while also intensifying pressure on the supply chain. Gross revenue, net sales after concessions and the Korean company's contractual receipts may move differently. The sources do not justify applying a general market discount directly to Bioepis revenue or treating patient savings as manufacturer profit. Useful follow-through would include the partner's product-level demand, inventory movement and settlements, with the relevant scope and period preserved. Company-wide biosimilar growth cannot automatically be allocated to this designation. A disciplined assessment would compare the cost of supporting all presentations with incremental retained contribution and collection timing. That approach gives the regulatory event its proper economic significance while keeping the unreported causal sales effect as a question rather than an invented result. 1. [Organon and Samsung Bioepis / expanded HADLIMA interchangeability](https://www.organon.com/news/us-food-and-drug-administration-fda-grants-interchangeability-designation-to-samsung-bioepis-and-organon-hadlima-adalimumab-bwwd-injection/) 2. [Organon / complete FY2025 Form 10-K, rights and product status](https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/ogn-20251231.htm) ## China - Reported connection Organon's filing excludes China from its described HADLIMA commercial-rights scope. This is a rights boundary, not a reported Chinese sale. ## Japan - DSML comparison Japanese product access would require separate regulatory and commercial evidence; US substitution status does not establish it. ## Other Asia - Reported connection The Korean developer supplies the product; South Korea is also excluded from Organon's stated rights scope. ## United States - Reported connection The additional designation concerns the US market and remains subject to state pharmacy laws. ## Europe - Reported connection The EU is excluded from Organon's stated commercial rights. The US announcement establishes no new EU event. ## Counterpoint Removing a prescribing or dispensing friction can have genuine commercial value even without an immediately disclosed sales effect. It may improve a partner's competitive offering. The opposing consideration is that access does not force payer preference, and incremental use can be less valuable if net pricing or inventory costs offset volume gains. ## Underwriting questions 1. Which payer and dispensing channels changed actual use after the designation? 2. What net-sales, supply-price and reporting terms determine Bioepis receipts? 3. How are presentation mix, inventory returns and working capital managed? ## Primary sources 1. [Organon and Samsung Bioepis / expanded HADLIMA interchangeability](https://www.organon.com/news/us-food-and-drug-administration-fda-grants-interchangeability-designation-to-samsung-bioepis-and-organon-hadlima-adalimumab-bwwd-injection/) (2025-05-27) 2. [Organon / complete FY2025 Form 10-K, rights and product status](https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/ogn-20251231.htm) (2026-02-24)